Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline

Lycia Therapeutics launched a U.S. IPO for its pipeline targeting food allergies and Graves' disease, aiming to raise up to $86 million.

Want to stay up to date with the world events at sea or at home?

Explore Navvyx News - the best News app for seafarers.